Literature DB >> 33782295

False-Positive 68Ga-Fibroblast Activation Protein-Specific Inhibitor Uptake of Benign Lymphoid Tissue in a Patient With Breast Cancer.

Cihan Gündoğan1, Yunus Güzel1, Canan Can1, Ulaş Alabalik2, Halil Kömek1.   

Abstract

ABSTRACT: 68Ga-fibroblast activation protein-specific inhibitor (FAPI)-04 PET/CT was performed in a patient with left lower outer quadrant breast cancer who had 18F-FDG PET/CT imaging. 68Ga-FAPI-04 PET/CT showed higher accumulation of radiotracer in primary tumor and axillary lymph nodes than 18F-FDG PET/CT. In addition, focal increased FAPI uptake was observed in another nodular lesion in the lower inner quadrant in the same breast, which was considered malignant. However, Tru-Cut biopsy of this lesion was reported as benign lymphoid tissue. This case showed that all FAPI accumulation in breast tissue should not be interpreted in favor of malignancy; histopathological confirmation is required.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33782295     DOI: 10.1097/RLU.0000000000003594

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  4 in total

1.  The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.

Authors:  Zahra Kiamanesh; Narjess Ayati; Ramin Sadeghi; Eliza Hawkes; Sze Ting Lee; Andrew M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-06       Impact factor: 10.057

Review 2.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

3.  Pitfalls and Common Findings in 68Ga-FAPI PET: A Pictorial Analysis.

Authors:  Lukas Kessler; Justin Ferdinandus; Nader Hirmas; Fadi Zarrad; Michael Nader; David Kersting; Manuel Weber; Sandra Kazek; Miriam Sraieb; Rainer Hamacher; Katharina Lueckerath; Lale Umutlu; Wolfgang P Fendler; Christoph Rischpler
Journal:  J Nucl Med       Date:  2021-10-07       Impact factor: 11.082

4.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.